2
Clinical Trials associated with β-globin restored autologous HSC(BRL Medicine Inc)a Safety and Efficacy Study of β-globin Restored Autologous Hematopoietic Stem Cells for β-thalassemia Major Patients With CVS-654 Mutation
This is a single center, single arm, open-label study to determine the safety and efficacy of β-globin restored autologous hematopoietic stem cells in β- thalassemia major patients with CVS-654 mutation.
/ Not yet recruitingPhase 1 A Single Center, Open Label Study to Evaluate the Safety and Efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients
This is an open label study to evaluate the safety and efficacy of β-globin Restored Autologous Hematopoietic Stem Cells in ß-Thalassemia Major Patients
100 Clinical Results associated with β-globin restored autologous HSC(BRL Medicine Inc)
100 Translational Medicine associated with β-globin restored autologous HSC(BRL Medicine Inc)
100 Patents (Medical) associated with β-globin restored autologous HSC(BRL Medicine Inc)
100 Deals associated with β-globin restored autologous HSC(BRL Medicine Inc)